jimmy Turano

These Small Cap Cancer Drugmakers Have Big Growth Potential

Justin, 'OUTSTANDING'. THERE ARE SO MANY INVESTORS WHO REALLY NEED HELP. THESE ARE THE ONES WHO I CALL MARRIED TO A STOCK, NO MATTER WHAT THEY READ, NO MATTER HOW BAD THE STATS, THE RATINGS, THEY CONTINUE TO HOLD ON, AND IN SOME CASES BUY MORE.
MDRNA INC(MRNA) IS A PERFECT EXAMPLE. IT IS NEVER MENTIONED ON SEEKING ALPHA, AND PROBABLY RIGHTFULLY SO. YET YOU WRITE AN OUTSTANDING ARTICLE, AND THE RESULTS SPEAK FOR THEMSELVES.
QUICK RETURNS, FROM GREAT RESEARCH ON YOUR PART.
YET OTHERS FLOUNDER, AND MAKE PREDICTIONS ON THE MESSAGE BOARDS LIKE GURU'S AND WANNA BE
ANALYSTS. YOU HAVE CLEARLY SHOWN, THAT YOU ARE SOME WHAT OF AN EXPERT, AND DESERVE TO BE A WRITER, RESEARCHER, FOR SEEKING ALPHA.
KEEP UP THE MARVELOUS WORK, AND MAYBE SOME WILL WAKE UP AND SMELL THE COFFEE FOR A CHANGE.

Biotech Day In Review: Agilent Buys Stratagene For $245.5 Million

SEEKING THIRD PARTY OPINION FROM ASTUTE INVESTOR, WHO HAS THE KNOWLEDGE,COURAGE AND GUTS TO EITHER CONCUR OR DISAGREE WITH THE FOLLOWING: IT IS IN MY OPINION THAT INVESTING IN 'NSTK' NOW IS NOT THE BEST THING TO DO WITH YOUR MONEY.
TWO YEARS AWAY FROM APPROVAL,IF APPROVED,POOR RATINGS,POOR FUNDAMENTALS,POOR MANAGEMENTS ABILITY TO TURN COMPANY AROUND, POOR EARNING REPORTS SCHEDULED FOR MAY REGARDING MARCH 2007 AND THE SAME FOR DECEMBER 2007. HAVING SAID THAT, THERE IS NO MOMENTUM, AND NO REASON FOR THE STOCK PRICE TO APPRECIATE IN THE COMING MONTHS AHEAD. SO ISN'T WISE TO INVEST IN OTHER POTENTIAL BIOTECH STOCKS IN THE MEANTIME? AM I RIGHT OR WRONG?
JT